387 related articles for article (PubMed ID: 30128808)
1. Highly sensitive and specific real-time PCR by employing serial invasive reaction as a sequence identifier for quantifying EGFR mutation abundance in cfDNA.
Xiang Z; Wan R; Zou B; Qi X; Huang Q; Kumar S; Pitman JL; Zhou G; Song Q
Anal Bioanal Chem; 2018 Oct; 410(26):6751-6759. PubMed ID: 30128808
[TBL] [Abstract][Full Text] [Related]
2. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
3. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
4. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
6. [Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].
Zhao J; Zhao J; Zhao X; Chen W; Zhong W; Zhang L; Li L; Wang M
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):25-32. PubMed ID: 23327870
[TBL] [Abstract][Full Text] [Related]
7. Multiplex-invasive reaction-assisted qPCR for quantitatively detecting the abundance of EGFR exon 19 deletions in cfDNA.
Tang Y; Zou B; Wang R; Luo N; Qi X; Zhou G; Song Q
Anal Methods; 2020 Jul; 12(26):3344-3350. PubMed ID: 32930221
[TBL] [Abstract][Full Text] [Related]
8. Rapid point-of-care testing for epidermal growth factor receptor gene mutations in patients with lung cancer using cell-free DNA from cytology specimen supernatants.
Asaka S; Yoshizawa A; Saito K; Kobayashi Y; Yamamoto H; Negishi T; Nakata R; Matsuda K; Yamaguchi A; Honda T
Int J Oncol; 2018 Jun; 52(6):2110-2118. PubMed ID: 29620164
[TBL] [Abstract][Full Text] [Related]
9. Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
Wang L; Guo Q; Yu W; Qiao L; Zhao M; Zhang C; Hu X; Yang G; Xiong L; Lou J
Lung Cancer; 2017 Dec; 114():31-37. PubMed ID: 29173762
[TBL] [Abstract][Full Text] [Related]
10. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
11. A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer.
Takata M; Chikumi H; Matsunami K; Kodani M; Sakamoto T; Hashimoto K; Nakamoto M; Okada K; Kitaura T; Matsumoto S; Kurai J; Yamasaki A; Igishi T; Burioka N; Shimizu E
Oncol Rep; 2015 Mar; 33(3):1040-8. PubMed ID: 25591975
[TBL] [Abstract][Full Text] [Related]
12. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
14. Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.
Akkhasutthikun P; Kaewsapsak P; Nimsamer P; Klomkliew P; Visedthorn S; Chanchaem P; Teerapakpinyo C; Payungporn S; Luangdilok S
Cancer Res Treat; 2024 Apr; 56(2):455-463. PubMed ID: 37986562
[TBL] [Abstract][Full Text] [Related]
15. A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
Sakamoto T; Kodani M; Takata M; Chikumi H; Nakamoto M; Nishii-Ito S; Ueda Y; Izumi H; Makino H; Touge H; Takeda K; Yamasaki A; Yanai M; Tanaka N; Igishi T; Shimizu E
Int J Oncol; 2015 Apr; 46(4):1473-80. PubMed ID: 25651992
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Study for Detection of
Kim Y; Shin S; Lee KA
Biomed Res Int; 2018; 2018():7392419. PubMed ID: 29854785
[TBL] [Abstract][Full Text] [Related]
18. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
20. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
